CD58 and hepatocellular carcinoma: According to the survival analysis, HCC patients with CD58-High expression had substantially lower overall survival times (Fig. 2f, p = 0.0013) and tumor-free survival times (Fig. 2g, p = 0.0183) than those with CD58-Low expression.